KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Sales (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Return on Sales for 13 consecutive years, with 4.22% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 372.0% to 4.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.43% through Dec 2025, up 889.0% year-over-year, with the annual reading at 2.43% for FY2025, 890.0% up from the prior year.
  • Return on Sales hit 4.22% in Q4 2025 for Arbutus Biopharma, up from 14.61% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.23% in Q2 2025 to a low of 14.73% in Q3 2024.
  • Historically, Return on Sales has averaged 6.75% across 5 years, with a median of 6.19% in 2021.
  • Biggest five-year swings in Return on Sales: plummeted -1041bps in 2024 and later skyrocketed 1170bps in 2025.
  • Year by year, Return on Sales stood at 6.65% in 2021, then surged by 47bps to 3.51% in 2022, then crashed by -156bps to 9.0% in 2023, then grew by 12bps to 7.94% in 2024, then soared by 47bps to 4.22% in 2025.
  • Business Quant data shows Return on Sales for ABUS at 4.22% in Q4 2025, 14.61% in Q3 2025, and 0.23% in Q2 2025.